title: Metformin as firstline treatment for type 2 diabetes: are we sure?
abstract: Rémy Boussageon and colleagues ask whether metformin is bringing practical benefit to patients and question the focus on surrogate measures.
authors.affiliation: Department of General Practice, Faculty of Poitiers, 86000 Poitiers, France remy.boussageon2@wanadoo.fr.
authors.forename: Rémy
authors.initials: R
authors.lastname: Boussageon
authors.affiliation: UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Claude Bernard University. CNRS, Lyon, France Louis Pradel Hospital, Lyon University, Lyon, France.
authors.forename: François
authors.initials: F
authors.lastname: Gueyffier
authors.affiliation: UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Claude Bernard University. CNRS, Lyon, France Louis Pradel Hospital, Lyon University, Lyon, France INSERM Clinical Investigation Centre (CIC1407), Lyon, France.
authors.forename: Catherine
authors.initials: C
authors.lastname: Cornu
mesh_terms: D015982:Bias; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D008687:Metformin / Q000008:administration & dosage*; D017410:Practice Guidelines as Topic
chemical_list: D007004:Hypoglycemic Agents; D008687:Metformin